X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antisense oligonucleotides (7) 7
index medicus (7) 7
2'-o-methoxyethyl (6) 6
humans (6) 6
medicine, research & experimental (6) 6
oligonucleotides (5) 5
proteins (4) 4
animals (3) 3
antisense (3) 3
biochemistry & molecular biology (3) 3
chemistry, medicinal (3) 3
drug dosages (3) 3
female (3) 3
male (3) 3
mutation (3) 3
oligonucleotides, antisense - therapeutic use (3) 3
original articles (3) 3
patients (3) 3
2′-o-methoxyethyl (2) 2
adult (2) 2
analysis (2) 2
article (2) 2
blood platelets (2) 2
cell biology (2) 2
clinical trials (2) 2
clinical trials, phase ii as topic (2) 2
diabetes (2) 2
diabetes mellitus (2) 2
dmd, duchenne muscular dystrophy (2) 2
double-blind method (2) 2
exon inclusion (2) 2
genetic therapy (2) 2
incidence (2) 2
inflammation (2) 2
inhibition (2) 2
liver (2) 2
middle aged (2) 2
monkeys (2) 2
monkeys & apes (2) 2
oligonucleotide (2) 2
original (2) 2
pharmaceuticals (2) 2
pharmacology (2) 2
platelets (2) 2
pmo, phosphorodiamidate morpholino (2) 2
rna-interference (2) 2
safety (2) 2
sma, spinal muscular atrophy (2) 2
studies (2) 2
thrombocytopenia (2) 2
thrombocytopenia - chemically induced (2) 2
toxicity (2) 2
2 (1) 1
2 '-o-methoxyethyl (1) 1
2 '-o-methyl (1) 1
2-o-methoxyethyl oligonucleotide (1) 1
2ʹ-moe, 2ʹ-o-methoxyethyl (1) 1
2ʹ-ome, 2ʹ-o-methyl (1) 1
2ʹ;-o-methoxyethyl oligonucleotide (1) 1
2′-o-methyl (1) 1
2′moe-ps, 2′-o-methoxyethyl phosphorothioate (1) 1
2′omeps, 2′-o-methyl phosphorothioate (1) 1
6mwt, 6-minute walk test (1) 1
abridged index medicus (1) 1
activation (1) 1
aged (1) 1
aged, 80 and over (1) 1
alga chlamydomonas-reinhardtii (1) 1
amyloid (1) 1
amyloid neuropathies, familial - blood (1) 1
amyloid neuropathies, familial - complications (1) 1
amyloid neuropathies, familial - therapy (1) 1
amyloidosis (1) 1
anatomy (1) 1
angioedema (1) 1
animal cells (1) 1
anrimir (1) 1
antagomir (1) 1
antimir (1) 1
antisense oligonucleorides (1) 1
antisense oligonucleotide (1) 1
antisense oligonucleotides, aso (1) 1
antisense-dna (1) 1
antisense-oligonukleotid (1) 1
aon, antisense oligonucleotide (1) 1
apolipoproteins (1) 1
apolipoproteins - antagonists & inhibitors (1) 1
apolipoproteins - genetics (1) 1
apolipoproteins - metabolism (1) 1
aso (1) 1
aso, antisense oligonucleotides (1) 1
attr amyloidosis (1) 1
b-cell lymphomas (1) 1
binding (1) 1
biochemistry (1) 1
biology and life sciences (1) 1
biotechnology & applied microbiology (1) 1
blood (1) 1
blood cells (1) 1
blood coagulation (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 1, pp. 22 - 31
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2017, Volume 12, Issue 11, pp. e0187574 - e0187574
Journal Article
Molecular Therapy - Nucleic Acids, ISSN 2162-2531, 12/2017, Volume 9, Issue C, pp. 242 - 250
Rapid progress has been made toward small interfering RNA (siRNA)-based therapy for human disorders, but rationally optimizing siRNAs for high specificity and... 
off target | 2′-O-methoxyethyl | siRNA | chemical modification | strand selection | RNA INTERFERENCE | TARGET | MEDICINE, RESEARCH & EXPERIMENTAL | IN-VITRO | PASSENGER STRAND | STABILITY | COMPLEXES | HUMAN RISC | CHEMICAL-MODIFICATION | MAMMALIAN-CELLS | OLIGONUCLEOTIDES
Journal Article
Nucleic Acid Therapeutics, ISSN 2159-3337, 02/2018, Volume 28, Issue 1, pp. 10 - 22
Systemically administered 2'-O-methoxyethyl (2'MOE) antisense oligonucleotides (ASOs) accumulate in the kidney and metabolites are cleared in urine. The... 
kidney | clinical trials | humans | safety | antisense | oligonucleotide | Hyperlipidemias - genetics | Receptors, Glucocorticoid - antagonists & inhibitors | Diabetes Mellitus - genetics | Humans | Middle Aged | Oligonucleotides, Antisense - metabolism | Male | Receptors, Glucocorticoid - metabolism | Obesity - genetics | Apolipoproteins - antagonists & inhibitors | Factor XI - antagonists & inhibitors | Clinical Trials, Phase III as Topic | Apolipoproteins - genetics | Oligonucleotides, Antisense - therapeutic use | Protein Tyrosine Phosphatases, Non-Receptor - genetics | Patient Safety | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Hyperlipidemias - physiopathology | Hyperlipidemias - therapy | Thrombosis - therapy | Factor XI - genetics | Thrombosis - physiopathology | Glomerular Filtration Rate | Hyperlipidemias - metabolism | Apolipoproteins - metabolism | Diabetes Mellitus - metabolism | Obesity - physiopathology | Receptor Protein-Tyrosine Kinases - metabolism | Obesity - metabolism | Randomized Controlled Trials as Topic | Thrombosis - metabolism | Oligonucleotides, Antisense - genetics | Receptor Protein-Tyrosine Kinases - genetics | Diabetes Mellitus - physiopathology | Diabetes Mellitus - therapy | Protein Tyrosine Phosphatases, Non-Receptor - metabolism | Obesity - therapy | Receptors, Glucocorticoid - genetics | Creatinine - blood | Thrombosis - genetics | Factor XI - metabolism | Clinical Trials, Phase II as Topic | Protein Tyrosine Phosphatases, Non-Receptor - antagonists & inhibitors | MEDICINE, RESEARCH & EXPERIMENTAL | CHEMISTRY, MEDICINAL | TARGETING APOLIPOPROTEIN(A) | BIOCHEMISTRY & MOLECULAR BIOLOGY | 2'-O-METHOXYETHYL | INHIBITION | DOUBLE-BLIND | ANTISENSE OLIGONUCLEOTIDES | Urine | Creatinine | Medical research | Renal function | Diabetes mellitus | Oligonucleotides | Clinical trials | Data processing | Antisense oligonucleotides | Dosage | Apolipoproteins | Patients | Clinical outcomes | Glomerular filtration rate | Incidence | Studies | Lipoproteins | Randomization | Metabolites | Diabetes | Kidney diseases | Drug dosages | Pharmaceuticals
Journal Article
Methods in Molecular Biology, ISSN 1064-3745, 2018, Volume 1828, pp. 69 - 76
Spinal muscular atrophy (SMA) is one of the most common genetic causes of infantile death arising due to mutations in the SMN1 gene and the subsequent loss of... 
Antisense oligonucleotides (ASOs) | Food and drug agency (FDA) | Survival of motor neuron (SMN) | Exon inclusion | SMN2 | Spinal muscular atrophy (SMA) | Werdnig–Hoffmann disease | 2'-O-methoxyethyl (MOE) | Intronic splicing silencer (ISS-N1) | Nusinersen (Spinraza) | Index Medicus
Journal Article
Bulletin of the Korean Chemical Society, ISSN 1229-5949, 11/2016, Volume 37, Issue 11, pp. 1754 - 1759
This research focused on the method of using dimeric phosphoramidite blocks to synthesize oligonucleotides for development as oligonucleotide drugs. A 16‐mer... 
2 | Dimer phosphoramidite block | Methoxyethyl oligonucleotide | Phosphoramidite | Solid‐phase synthesis | 2ʹ;-O-methoxyethyl oligonucleotide | Solid-phase synthesis | THERAPEUTICS | 2-O-Methoxyethyl oligonucleotide | DEOXYRIBOPOLYNUCLEOTIDES | CONDENSATION | POLYNUCLEOTIDES | CHEMISTRY, MULTIDISCIPLINARY | RNA-INTERFERENCE
Journal Article
EBioMedicine, ISSN 2352-3964, 07/2019, Volume 45, pp. 630 - 645
Duchenne muscular dystrophy (DMD) is an X-linked disorder characterized by progressive muscle degeneration, caused by the absence of dystrophin. Exon skipping... 
MEDICINE, RESEARCH & EXPERIMENTAL | OLIGONUCLEOTIDE THERAPY | IN-VIVO DELIVERY | MORPHOLINO OLIGOMERS | NITRIC-OXIDE SYNTHASE | CELL-PENETRATING PEPTIDES | CARDIAC-MUSCLE | EXON-SKIPPING THERAPY | RECEPTOR-MEDIATED UPTAKE | MOUSE MODELS | MDX MICE
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.